NULL NULL
Man and woman smiling at a group.

PATIENT SUPPORT

PADCEV Support SolutionsSM is here to help

PADCEV Support SolutionsSM offers support to help patients access their medication.

Man and woman. Not actual patients.

PADCEV Support SolutionsSM offers support to help patients access their medication.

Call PADCEV Support Solutions at
1-888-402-0627

Monday-Friday, 8:30 AM to 8:00 PM ET

Visit the PADCEV Support
Solutions website
if you have any
questions or need assistance.

We can help evaluate your insurance coverage

PADCEV Support Solutions offers information to help you understand your insurance coverage for PADCEV®. PADCEV Support Solutions will provide your healthcare professional with a summary of your insurance benefits. We can also help determine if your insurer requires a prior authorization (PA). If your insurer denies a PA request, and your healthcare professional determines that an appeal is appropriate, PADCEV Support Solutions can assist with the appeal.

PADCEV Support Solutions offers patient assistance options and financial assistance information

Copay Assistance Program

The PADCEV Copay Assistance Program is for eligible patients who have private commercial health insurance and are not insured by any federal or state healthcare program. Eligible patients pay as little as $5 per dose and are enrolled in the program for 12 months. Under the program, eligible patients may save up to a maximum of $25,000 per calendar year. There are no income requirements.1

Patient Assistance Program

The PADCEV Patient Assistance Program provides PADCEV at no cost to uninsured patients who meet the program eligibility requirements.2

Financial Assistance Information

For patients who need financial assistance to help cover out-of-pocket costs, PADCEV Support Solutions can provide information about other sources of support that may be able to help.

1In order to participate in the PADCEV Copay Assistance Program (“Program”), a patient must have private commercial insurance for PADCEV. The Program is not valid for patients insured by any federal or state healthcare program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patients or pharmaceutical assistance program. This offer is not valid for cash-paying patients. This Program is void where prohibited by law. Astellas reserves the right to revoke, rescind, or amend this offer without notice. The Program benefits are nontransferable. This Program is not conditioned on any past, present, or future purchase, including additional doses. The benefit available under this Program is valid only for the patient’s out-of-pocket medication costs for PADCEV. The benefit is not valid for any other out-of-pocket costs such as medication administration charges or other healthcare provider services. The Program Is Not Insurance.

2Subject to eligibility. Void where prohibited by law.

Patient Connect

PADCEV Support Solutions, through the Patient Connect Program, offers additional patient and caregiver support to people like you who have been prescribed PADCEV. This program helps connect you and your loved ones to educational resources and support based on your particular needs to help you manage your disease and daily life while on treatment.

When you call PADCEV Support Solutions, a trained representative will speak with you to understand the types of challenges you may be facing and will customize a search of various independent local and national organizations3 that may provide support and resources right for you and your loved ones. Examples may include:

Emotional support icon.

Emotional Support

Social workers, counseling services, or online communities for you

Emotional support for your family members and friends

Logistical support icon.

Logistical Support

Transportation and lodging assistance to get you to/from appointments

Help with other day-to-day tasks

Informational support icon.

Informational Support

Other education and resources about the patient’s disease and treatment

Advice and recommendations on nutrition and self-care

3Support is provided through third-party organizations that operate independently and are not controlled or endorsed by Astellas or Seagen. Availability of support and eligibility requirements are determined by these organizations.

Call PADCEV Support Solutions at
1-888-402-0627

Monday-Friday, 8:30 AM to 8:00 PM ET

Visit the PADCEV Support
Solutions website
if you have any
questions or need assistance.

Related topics

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Severe skin reactions have happened in people treated with PADCEV; in some cases severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Your healthcare provider will monitor you during treatment and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV (enfortumab vedotin-ejfv) Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

have liver problems

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

Infusion icon.

How will I receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “Skin Reactions” above for more information.

High blood sugar icon.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. High blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes who were treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems icon.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV include:

skin rash

changes in liver and kidney function tests

increased sugar (glucose) in the blood

tiredness

numbness or tingling in your hands or feet, or muscle weakness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a blood test done to check your pancreas)

decreased weight

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Severe skin reactions have happened in people treated with PADCEV; in some cases severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Your healthcare provider will monitor you during treatment and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV (enfortumab vedotin-ejfv) Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

have liver problems

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

Infusion icon.

How will I receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “Skin Reactions” above for more information.

High blood sugar icon.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. High blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes who were treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems icon.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV include:

skin rash

changes in liver and kidney function tests

increased sugar (glucose) in the blood

tiredness

numbness or tingling in your hands or feet, or muscle weakness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a blood test done to check your pancreas)

decreased weight

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Severe skin reactions have happened in people treated with PADCEV; in some cases severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle (28 days) of treatment but may happen later. Your healthcare provider will monitor you during treatment and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings)

rash or itching that continues to get worse

blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area

fever or flu-like symptoms

swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

PADCEV (enfortumab vedotin-ejfv) Important Safety Information icon.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

are currently experiencing numbness or tingling in your hands or feet

have a history of high blood sugar or diabetes

have liver problems

are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV

are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV

Pregnancy warning for females icon.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.

You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Pregnancy warning for male partners icon.

Males with a female sexual partner who is able to become pregnant:

If your female partner is pregnant, PADCEV can harm the unborn baby.

You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Drug interactions icon.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

Infusion icon.

How will I receive PADCEV?

PADCEV will be given to you by intravenous (IV) infusion into your vein over 30 minutes.

You will receive your PADCEV over periods of time called cycles.

- Each PADCEV cycle is 28 days.

- You will receive PADCEV on days 1, 8 and 15 of every cycle.

Your healthcare provider will decide how many treatment cycles you need.

Your healthcare provider may do blood tests regularly during treatment with PADCEV.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions icon.

Skin Reactions. See “Skin Reactions” above for more information.

High blood sugar icon.

High Blood Sugar (hyperglycemia). You can develop high blood sugar during treatment with PADCEV. High blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes who were treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.

Lung problems icon.

Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.

Hand with peripheral neuropathy icon.

Peripheral neuropathy. You may develop nerve problems called peripheral neuropathy during treatment with PADCEV. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet, or muscle weakness.

Eye problems icon.

Eye problems. You can develop certain eye problems during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.

Infusion site (extravasation) icon.

Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, or discomfort at the infusion site.

The most common side effects of PADCEV include:

skin rash

changes in liver and kidney function tests

increased sugar (glucose) in the blood

tiredness

numbness or tingling in your hands or feet, or muscle weakness

decreased white blood cell, red blood cell, and platelet counts

hair loss

decreased appetite

diarrhea

decreased sodium, phosphate and protein (albumin) in the blood

nausea

itching

change in sense of taste

increased uric acid in the blood

increased lipase (a blood test done to check your pancreas)

decreased weight

dry skin

If you have certain side effects, your healthcare provider may decrease your dose or stop your treatment with PADCEV for a period of time (temporarily) or completely.

PADCEV may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Communicate with your doctor icon.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:

have received an immunotherapy medicine and chemotherapy that contains platinum, or

you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.

It is not known if PADCEV is safe and effective in children.

Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.

© 2022 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0681-PM 06/22
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.


© 2022 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0681-PM 06/22
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.

© 2022 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0681-PM 06/22
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.


© 2022 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-0681-PM 06/22
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.